Business
Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
Supply agreement reflects Moderna’s commitment to make its vaccine available in Africa Botswana Medicines Regulatory Authority issues emergency use
About this update from Moderna, Inc.
[{"type":"text","content":"\nSupply agreement reflects Moderna’s commitment to make its vaccine available in Africa\n\nBotswana Medicines Regulatory Authority issues emergency use authorization (EUA) for COVID-19 Vaccine Moderna\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the Government of the Republic of Botswana for Moderna’s vaccine against COVID-19, to support the government’s ongoing efforts to secure access to a COVID-19 vaccines for the people of Botswana. The Company also announced that the Botswana Medicines Regulatory Authority (BMRA) has issued an emergency use authorization for the COVID-19 Vaccine Moderna.\n\n“We appreciate the collaboration with the Government of the Republic of Botswana for this supply agreement and with the Botswana Medicines Regulatory Authority for this EUA,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We are committed to ensuring that people on every continent have access to our mRNA vaccine so that we can defeat the COVID-19 pandemic.”\n\nThis agreement with Botswana is separate from the supply agreement with Gavi, the Vaccine Alliance, which Moderna announced in May. The agreement with Gavi, on behalf of the COVAX Facility, is for the supply of up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. COVAX is a global initiative co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.\n\nAuthorized Use\n\nThe COVID-19 Vaccine Moderna has been granted emergency use authorization by the Botswana Medicines Regulatory Authority for use in adults aged 18 years and older.\n\nAbout the COVID-19 Vaccine Moderna\n\nThe COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparednes...